Aldeyra Therapeutics (ALDX) Accounts Payables (2013 - 2026)
Aldeyra Therapeutics' (ALDX) quarterly Accounts Payables came in at $141356.0 in Q1 2026, down 59.16% YoY from $346146.0 in Q1 2025, and down 10.79% on a QoQ basis from $158461.0 in Q4 2025.
Aldeyra Therapeutics (ALDX) Accounts Payables (2013 - 2026) Analysis & Trends
Aldeyra Therapeutics (ALDX) has 14 years of Accounts Payables data on file, last reported at $141356.0 in Q1 2026.
- Quarterly Accounts Payables fell 59.16% year-over-year to $141356.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $141356.0 (down 59.16% YoY) and the FY2025 annual result came in at $158461.0, down 12.19% from the prior year.
- Accounts Payables declined to $141356.0 in Q1 2026, from $158461.0 in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $2.4 million in Q1 2022 to a low of $13423.0 in Q3 2025.
- A 5-year average of $555889.4 and a median of $264225.0 in 2022 frame the typical range for Accounts Payables.
- Annual changes were most pronounced in 2023 — Accounts Payables jumped 901.35% — and 2025, when it plunged 92.82%.
- Tracing ALDX's Accounts Payables over 5 years: stood at $133625.0 in 2022, then jumped by 901.35% to $1.3 million in 2023, then tumbled by 86.51% to $180453.0 in 2024, then fell by 12.19% to $158461.0 in 2025, then declined by 10.79% to $141356.0 in 2026.
- The last three Accounts Payables figures came in at $141356.0 (Q1 2026), $158461.0 (Q4 2025), and $13423.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Aldeyra Therapeutics | 90.18 Mn | 90.18 Mn | - | 137,476.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 137,476.00 |
| Mar 31, 2026 | 141,356.00 |
| Dec 31, 2025 | 158,461.00 |
| Sep 30, 2025 | 13,423.00 |
| Jun 30, 2025 | 1.46 Mn |
| Mar 31, 2025 | 346,146.00 |
| Dec 31, 2024 | 180,453.00 |
| Sep 30, 2024 | 186,919.00 |
| Jun 30, 2024 | 254,434.00 |
| Mar 31, 2024 | 280,299.00 |
| Dec 31, 2023 | 1.34 Mn |
| Sep 30, 2023 | 247,194.00 |
| Jun 30, 2023 | 270,816.00 |
| Mar 31, 2023 | 429,685.00 |
| Dec 31, 2022 | 133,625.00 |
| Sep 30, 2022 | 1.31 Mn |
| Jun 30, 2022 | 264,225.00 |
| Mar 31, 2022 | 2.44 Mn |
| Dec 31, 2021 | 1.02 Mn |
| Sep 30, 2021 | 467,932.00 |